/
© 2026 RiffOn. All rights reserved.

Get your free personalized podcast brief

We scan new podcasts and send you the top 5 insights daily.

  1. Research To Practice | Oncology Videos
  2. Chronic Lymphocytic Leukemia — Microlearning Activity 1
Chronic Lymphocytic Leukemia — Microlearning Activity 1

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos · Oct 15, 2026

Drs. Love and Coombs examine evolving CLL therapies, from delayed triplet regimens and MRD-guided strategies to pirtobrutinib safety.

Delay Obinutuzumab in CLL Triplet Regimens to Drastically Reduce Severe Myelosuppression

Pre-clearing disease burden with acalabrutinib and venetoclax enables bone marrow recovery prior to introducing obinutuzumab. This delayed addition strategy noticeably improves safety, leading to fewer severe infusion reactions, reduced myelosuppression, and lower potential infection risks compared to early triplet dosing.

Chronic Lymphocytic Leukemia — Microlearning Activity 1 thumbnail

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos·a month ago

Avoid Escalating to Triplet Therapy for Mutated IGHV CLL Despite Positive Residual Disease

Patients with mutated IGHV achieve undetectable MRD less frequently on oral doublets than unmutated patients, but still demonstrate extended progression-free survival due to indolent biology. Adding an anti-CD20 antibody like obinutuzumab risks overtreating a favorable subgroup that already achieves durable disease control without third-agent toxicities.

Chronic Lymphocytic Leukemia — Microlearning Activity 1 thumbnail

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos·a month ago

Elective BTK Inhibitor Discontinuation Demands at Least Two Years of Continuous Therapy

While patients often request drug vacations due to cost and chronic reminders of cancer, stopping therapy prematurely risks rapid relapse. Clinicians emphasize that attempting planned discontinuation requires at least two years on drug and an established clinical response, although prospective randomized validation remains ongoing.

Chronic Lymphocytic Leukemia — Microlearning Activity 1 thumbnail

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos·a month ago

Undetectable MRD Endpoints Matter Little for Patients on Continuous BTK Inhibitors

Academic focus on deep remission diverges from clinical practice during continuous BTK inhibitor therapy, where clone suppression sustains progression-free survival for six to seven years without clone obliteration. Undetectable MRD is primarily a necessary benchmark for time-limited approaches rather than indefinitely maintained regimens.

Chronic Lymphocytic Leukemia — Microlearning Activity 1 thumbnail

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos·a month ago

Reserve Frontline Pirtobrutinib for Comorbid CLL Patients Due to Cross-Resistance Concerns

Despite demonstrating favorable cardiac tolerability with low rates of atrial fibrillation, non-covalent pirtobrutinib poses unresolved sequencing concerns. Clinicians worry that frontline pirtobrutinib could induce cross-resistance preventing subsequent covalent BTK efficacy, leading them to restrict upfront use strictly to patients with substantial cardiovascular comorbidities.

Chronic Lymphocytic Leukemia — Microlearning Activity 1 thumbnail

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos·a month ago

Sonrotoclax Achieves Superior 90% Undetectable MRD Rates in Frontline Oral Doublets

Preclinical findings demonstrating tenfold higher potency for sonrotoclax over venetoclax are supported by clinical trials evaluating sonrotoclax alongside zanubrutinib. Frontline data reveal undetectable MRD rates reaching approximately 90%, far surpassing the 30% to 50% benchmarks historically observed with venetoclax-based oral doublets.

Chronic Lymphocytic Leukemia — Microlearning Activity 1 thumbnail

Chronic Lymphocytic Leukemia — Microlearning Activity 1

Research To Practice | Oncology Videos·a month ago